Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
The US Biomedical Advanced Research and Development Authority will provide up to $1.2 billion to AstraZeneca to accelerate work on an adenoviral vector vaccine for COVID-19 that the UK drug firm licensed from the University of Oxford. The UK government is providing about $80 million to the effort. AstraZeneca says it has finalized agreements for at least 400 million doses of the vaccine, AZD1222, and has secured production capacity for 1 billion doses. Deliveries could begin in September under a fair allocation program the firm is developing.
C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.
This article has been sent to the following recipient: